Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAP-ACE: TACE + Camrelizumab + Apatinib in HCC
NCT04559607Phase 2Active, not recruiting
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Sep 2020
- Primary completion
- Aug 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Zhongda Hospital, Southeast University. Primary endpoint: Progression-free survival at 2 years. Started Sep 2020; status: active, not recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04559607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04559607.